Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
Omicron KP.3 RBD-Containing Spike mRNA Vaccine Induces Broadly Neutralizing Antibodies with Protection Against
Xiaoqing Guan1, Hansam Cho1, Shengnan Qian1
1Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
A novel mRNA vaccine targeting the Omicron-KP.3 receptor-binding domain (RBD) shows broad neutralization against Omicron subvariants. This vaccine demonstrated stability, potent immunogenicity, and protective efficacy in a mouse model against SARS-CoV-2 Omicron-KP.3.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in millions of deaths globally.
- Omicron subvariants exhibit immune escape, necessitating vaccines with broad neutralization capabilities.
- The spike protein's receptor-binding domain (RBD) is a critical target for vaccine development.
Purpose of the Study:
- To design and evaluate a novel mRNA vaccine encoding the Omicron-KP.3 RBD.
- To assess the vaccine's stability, immunogenicity, neutralizing activity, and protective efficacy against SARS-CoV-2 Omicron subvariants.
Main Methods:
- Development of a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine (KP3 mRNA) based on an RBD-truncated S protein backbone.
- Evaluation of vaccine stability at various temperatures.
- Assessment of immunogenicity, neutralizing antibody titers, and protective efficacy in a mouse model.
Main Results:
- The KP3 mRNA vaccine demonstrated stability across different temperatures.
- The vaccine induced potent antibody responses with broad neutralizing activity against multiple Omicron subvariants (KP.2, KP.3, XEC, NB.1.8.1).
- Vaccinated mice were protected against SARS-CoV-2 Omicron-KP.3 challenge, with protection correlating positively with neutralizing antibody titers.
Conclusions:
- The designed mRNA vaccine shows promise for combating current and future Omicron subvariants.
- This vaccine strategy offers a potential approach for broad protection against evolving SARS-CoV-2 variants.
- Further development could lead to effective vaccines against emerging Omicron strains.
More Related Videos
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
10:25Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
Related Concept Videos
Vaccinations
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
Regulated mRNA Transport
Nuclear Export of mRNA